genprowebdirectory
Facebook
Linkedin
RSS
Twitter
Youtube
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Search
Facebook
Linkedin
RSS
Twitter
Youtube
Sign in
Welcome! Log into your account
your username
your password
Forgot your password? Get help
Privacy Policy
Password recovery
Recover your password
your email
A password will be e-mailed to you.
GEN – Genetic Engineering and Biotechnology News
GEN Edge
Featured News
Multimedia
News
Insights
Topics
Artificial Intelligence
Bioprocessing
Cancer
Drug Discovery
Genome Editing
Infectious Diseases
OMICs
Translational Medicine
Magazine
Browse Issues
Subscribe
Multimedia
Summits
Webinars
GEN Live
Learning Labs
Podcasts
Resources
A-Lists
eBooks/Perspectives
Tutorials
Peer-Reviewed Journals
GEN Biotechnology
Re:Gen Open
New Products
Conference Calendar
Subscribe
Get GEN Magazine
Get GEN eNewsletters
Home
2014
Ariad Pharmaceuticals
Cancer
Angelini to Commercialize Iclusig in Central, Eastern Europe
News
Ariad Generates Buzz of Potential Big-Pharma Buyers
Cancer
Ariad’s Iclusig Returns to U.S. Commercial Market
A-Lists
Top 10 Wall Street Losers of 2013
Cancer
Ariad Cuts 160 U.S. Jobs One Week after Pulling Iclusig from Market
Cancer
Ariad Ends Phase III Leukemia Drug Trial
Insights
2012 Has the Makings of a Breakout Year
Cancer
Ariad Reports Positive Preliminary Results from Pivotal Ponatinib CML Trial
Cancer
Ariad Inks Three Separate Deals Covering Argent Technology
Cancer
Ariad Reports Phase III Success with Drug for Metastatic Soft-Tissue or Bone Sarcomas
1
2
3
Page 2 of 3
Scroll Up